SOUTH SAN FRANCISCO (dpa-AFX) – Phase III OCARINA II trial, which evaluated Ocrevus (ocrelizumab) as a twice a year 10-minute subcutaneous injection, met its primary and secondary endpoints in patients with relapsing forms of Multiple sclerosis or primary progressive Multiple sclerosis, Genentech, a member of the Roche Group (RHHBY), said…Read More
Genentech Phase III Trial Of Ocrevus In Multiple Sclerosis Meets Primary And Secondary Endpoints
